VIATRIS INC. Proceeds from Divestiture of Businesses
VIATRIS INC. (VTRS) reported Proceeds from Divestiture of Businesses of $2.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2026-02-26
- VIATRIS INC. proceeds from divestiture of businesses for the quarter ending 2025-12-31 was $2.50M.
- VIATRIS INC. proceeds from divestiture of businesses for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from divestiture of businesses for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from divestiture of businesses for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from divestiture of businesses for fiscal 2025 was $2.50M, a 99.90% decline from fiscal 2024.
- VIATRIS INC. proceeds from divestiture of businesses for fiscal 2024 was $2.51B, a 588.57% increase from fiscal 2023.
- VIATRIS INC. proceeds from divestiture of businesses for fiscal 2023 was $364.10M, a 81.33% decline from fiscal 2022.
- VIATRIS INC. proceeds from divestiture of businesses for fiscal 2022 was $1.95B, a 1916.55% increase from fiscal 2021.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.50M derived: sum of 2 quarters · filed 2026-02-26 | $2.50M derived: sum of 3 quarters · filed 2026-02-26 | $2.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$3.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$3.10M derived: sum of 3 quarters · filed 2026-02-26 | $1.83B derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$3.10M derived: sum of 2 quarters · filed 2026-02-26 | $1.83B derived: sum of 3 quarters · filed 2026-02-26 | $2.27B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.83B derived: sum of 2 quarters · filed 2026-02-26 | $2.27B derived: sum of 3 quarters · filed 2026-02-26 | $2.51B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.83B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.27B derived: sum of 2 quarters · filed 2025-11-06 | $2.51B 10-Q · filed 2025-11-06 | $2.83B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $437.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $677.70M 10-Q · filed 2025-08-07 | $993.80M derived: sum of 3 quarters · filed 2026-02-26 | $1.04B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $240.60M 10-Q · filed 2025-05-08 | $556.70M derived: sum of 2 quarters · filed 2026-02-26 | $604.70M derived: sum of 3 quarters · filed 2026-02-26 | $604.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $316.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $364.10M derived: sum of 2 quarters · filed 2026-02-26 | $364.10M derived: sum of 3 quarters · filed 2026-02-26 | $364.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $48.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $48.00M derived: sum of 2 quarters · filed 2024-11-07 | $48.00M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $1.95B 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $96.70M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $20.00M 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $28.00M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $29.30M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |